AstraZeneca Expands U.S. Footprint to Power the Future of Cell Therapy
AstraZeneca’s investment in Maryland creates high-quality jobs and advances next-generation cancer treatments.
AstraZeneca has announced the opening of a sustainable, state-of-the-art cell therapy manufacturing facility in Rockville, Maryland. This site will bring over 150 highly skilled STEM jobs to the region and boost the local economy. The facility will support clinical trials for next-generation T-cell therapies aimed at treating some of the most challenging cancers and diseases, building on America’s leadership in cancer therapy innovation.
This investment is part of a broader U.S. expansion that includes R&D hubs and advanced manufacturing sites across the country. It is a manifestation of AstraZeneca’s commitment to cutting-edge innovation, community investment and U.S. manufacturing leadership. In the words of Maryland Lieutenant Governor Aruna Miller, “AstraZeneca isn’t just advancing science, it’s also shaping the future of Maryland’s workforce.”

Our Work in Action
To maintain America’s global leadership, we need to support the next generation of innovation in medicine.